Gland Pharma Limited — Important, 26-02-2025: Updates

The Board of Directors of Gland Pharma Limited has approved the Gland Pharma Employee Stock Option Scheme, 2025, for granting stock options to eligible employees. The scheme's details indicate that a total of 29,82,124 shares will be available under the plan, with options granted based on performance criteria determined by the ESOP Compensation Committee. The options will have varying exercise prices, with a maximum discount of 50% on the market price or a minimum of ₹750, whichever is higher.

The options are set to vest between one to four years from the grant date, manageable by the compensation committee. The exercise period for vested options will extend to two years after vesting. This initiative aims to enhance employee retention and motivation, which could have a positive long-term impact on the company's performance. Shareholders' approval will be sought via postal ballot for the scheme to proceed, making it a pivotal step in aligning employee interests with the company’s growth trajectory. Investors should monitor this development for potential impacts on employee engagement and company performance.